Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts
Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.